Trial Profile
Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Ixabepilone (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel
- Indications Early breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms TITAN
- 01 Mar 2017 Status changed from active, no longer recruiting to completed.
- 28 Jan 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
- 27 Jan 2015 Planned End Date changed from 1 Jan 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov record.